U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment
(Reuters) - The U.S. government on Friday signed an agreement with AstraZeneca Plc <AZN.L> worth $ 486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of Medicines that were used to treat President Donald Trump.
The U.S. Department of Public Health will provide AstraZeneca with funding for two Phase 3 clinical trials under Operation Warp Speed, which aim to expedite treatments and vaccines for COVID-19.
One study will evaluate the safety and effectiveness of experimental treatment to prevent infection for up to 12 months in approximately 5,000 participants, while the second study will evaluate preventive and preventive treatment after exposure in approximately 1,100 participants.
AstraZeneca plans to ship up to 100,000 cans by the end of 2020 and the US government may purchase up to an additional million cans in 2021 under a separate agreement.
In a video posted on Twitter on Wednesday, Trump attributed Regeneron Pharmaceuticals Inc.'s <REGN.O> therapeutic agent for his recovery. Trump received Regeneron's treatment last week after he was diagnosed with COVID-19.
(Reporting by Ankur Banerjee in Bengaluru; editing by Anil D'Silva)
You should check here to buy the best price guaranteed products.
Chris Rock explains why he turned down 'a couple offers' to be on The Sopranos
Biden dismisses Putin’s comparison between Capitol rioters and political opponents
John Legend Shares Update on Chrissy Teigen Amid Bullying Controversy
Biden gifts Putin crystal bison sculpture, pair of custom Aviators
Joe Biden, At End Of Post Summit Press Conference, Gets Irked At CNN’s Kaitlan Collins Over Vladimir Putin Question; President Later Apologizes For Being “Wiseguy”
Dallas Mavericks part ways with long-time president of basketball operations Donnie Nelson